AI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous, writes Margaretta Colangelo.
Dmitry Kaminskiy
Advertisement
Dmitry Kaminskiy is General Partner, Deep Knowledge Ventures
Articles by Dmitry Kaminskiy
Advertisement
Latest Updated Articles
Specialized Metrics to Properly Assess AI-Pharma StartupsPublished: April 18th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina
2
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
3
Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape
4
AstraZeneca to Announce Deal with Trump Administration: Report
5
